<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875056</url>
  </required_header>
  <id_info>
    <org_study_id>0683-103</org_study_id>
    <secondary_id>2009_570</secondary_id>
    <secondary_id>132248</secondary_id>
    <nct_id>NCT00875056</nct_id>
  </id_info>
  <brief_title>Study of Vorinostat (MK0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL) Patients (MK-0683-103)</brief_title>
  <official_title>A Phase II Study of MK0683 in Patients With Relapsed / Refractory Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates safety and tolerability of MK0683 and efficacy of MK0683 in patients
      with relapsed and/or refractory FL. Exploratory purpose of this study is to evaluate efficacy
      of MK0683 in patients with relapsed and/or refractory other Indolent B-NHL or MCL.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 15, 2009</start_date>
  <completion_date type="Anticipated">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">February 25, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>21 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to event efficacy endpoints 2)Any clinical or laboratory adverse experiences</measure>
    <time_frame>21 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vorinostat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>MK0683 (200 mg capsule) Oral, twice daily (400 mg/day) for Day 1 through 14 of a 21 day cycle</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient Is 20 To 74 Years Old

          -  Patient Has An Histopathologically Confirmed Fl, Or Other Indolent B-Nhl Or Mcl (Only
             Relapsed / Refractory Fl Can Be Included Outside Japan.)

          -  Patient Has At Least One Measurable Lesion By Ct Scan Which Is Defined By Cheson's
             1999 Criteria

          -  Patient Has Received At Least 1 But Up To 4 Prior Chemotherapeutic Regimen, The Most
             Recent Therapy Must Have Failed To Induce A Partial Response, Or There Must Be
             Recurrence In Case Of The Most Recent Therapy Has Shown Complete Response, Or There
             Must Be Relapse In Case Of The Most Recent Therapy Has Shown Partial Response.

          -  Patient Must Have Adequate Organ And Marrow function

        Exclusion Criteria:

          -  Patient Who Has Undergone Allogenic Transplant Treatment Or Autologous Stem Cell
             Transplant Within 6 Months

          -  Patient With Other Active Malignancies Or Central Neurological Infiltration With
             Lymphoma

          -  Patient With Severe Hepatic Insufficiency

          -  Patient With History Of Allergic Reactions Attributed To Any Component Of MK0683

          -  Patient Who Is Known To Be HIV Antibody-, Hbv Antigen- Or Hcv Antibody-Positive

          -  Patient Who Has Undergone Prior/Concomitant Treatment With MK0683 Or Other Hdac
             Inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </removed_countries>
  <results_reference>
    <citation>Ogura M, Ando K, Suzuki T, Ishizawa K, Oh SY, Itoh K, Yamamoto K, Au WY, Tien HF, Matsuno Y, Terauchi T, Yamamoto K, Mori M, Tanaka Y, Shimamoto T, Tobinai K, Kim WS. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2014 Jun;165(6):768-76. doi: 10.1111/bjh.12819. Epub 2014 Mar 12.</citation>
    <PMID>24617454</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2009</study_first_submitted>
  <study_first_submitted_qc>April 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2009</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

